|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Grant and award revenue | |||||
| Operating expenses | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment expense | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income (expense) | |||||
| Interest income | |||||
| Interest expense | |||||
| Change in fair value of the Convertible Loan | |||||
| Gain on debt and the Convertible Loan extinguishments | |||||
| Total other income (expense), net | |||||
| Net loss | |||||
| Per share information: | |||||
| Net loss per share, basic | |||||
| Weighted average shares outstanding, basic | |||||
| Net loss per share, diluted | |||||
| Weighted average shares outstanding, diluted | |||||
Loading...
